![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan (M.K., H.S., M.K.); Department of Pharmacy, Sapporo City General Hospital, Sapporo, Japan (K.T., Y.T.); and Department of Renal Transplantation, Sapporo City General Hospital, Sapporo, Japan (T.H.)
The onset of diarrhea after the administration of mycophenolate mofetil (MMF) is possibly associated with the biliary excretion of its metabolite, mycophenolic acid glucuronide (MPAG). This study was undertaken to clarify the mechanism underlying the biliary excretion of MPAG. Intravenously administered mycophenolic acid (MPA, 5 mg/kg) rapidly disappeared from plasma and was efficiently excreted as MPAG in the bile of Wistar (26% of dose) and Sprague-Dawley rats (21% of dose) over 1 h. On the other hand, in spite of the rapid disappearance of MPA from plasma, the biliary excretion of MPAG was very limited in Eisai hyperbilirubinemic rats (EHBRs), which display mutations in multidrug resistance-associated protein 2 (Mrp2)/canalicular multispecific organic anion transporter, and constituted only 0.5% of dose. Instead, high levels of MPA were noted in the plasma of EHBRs. Intravenous administration of CsA (5 mg/kg) to Wistar rats significantly lowered the biliary excretion of MPAG. However, intravenously administered tacrolimus (0.1 mg/kg) failed to produce such effect. In conclusion, it is suggested that there is an efficient MPAG transport mediated by Mrp2 on the bile canalicular membrane of rat hepatocytes and that the therapeutic range of CsA potentially interferes with Mrp2. However, the therapeutic range of tacrolimus does not inhibit the transporter. Thus, it should be noted that MMF coadministered with tacrolimus instead of CsA might increase the occurrence of diarrhea related to the biliary excretion of MPAG in transplant recipients.
Address correspondence to: Dr. Hiroshi Saitoh, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Kanazawa 1757, Ishikari-Tobetsu, Hokkaido 061-0293, Japan. Email: saitoh{at}hoku-iryo-u.ac.jp
This article has been cited by other articles:
|
|
 |
|
  I. S. Westley, R. G. Morris, A. M. Evans, and B. C. Sallustio Glucuronidation of Mycophenolic Acid by Wistar and Mrp2-Deficient TR- Rat Liver Microsomes Drug Metab. Dispos., January 1, 2008; 36(1): 46 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Shaw, M. Figurski, M. C. Milone, J. Trofe, and R. D. Bloom Therapeutic Drug Monitoring of Mycophenolic Acid Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 1062 - 1072. [Full Text] [PDF]
|
|
|
|
|
|
S. T. Stern, M. N. Tallman, K. K. Miles, J. K. Ritter, R. E. Dupuis, and P. C. Smith Gender-Related Differences in Mycophenolate Mofetil-Induced Gastrointestinal Toxicity in Rats Drug Metab. Dispos., March 1, 2007; 35(3): 449 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jacobson, K. Green, J. Rogosheske, C. Brunstein, B. Ebeling, T. DeFor, P. McGlave, and D. Weisdorf Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation J. Clin. Pharmacol., January 1, 2007; 47(1): 6 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jeong and B. Kaplan Therapeutic Monitoring of Mycophenolate Mofetil Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 184 - 191. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zamek-Gliszczynski, K. A. Hoffmaster, J. E. Humphreys, X. Tian, K.-i. Nezasa, and K. L. R. Brouwer Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 459 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Westley, L. R. Brogan, R. G. Morris, A. M. Evans, and B. C. Sallustio ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE Drug Metab. Dispos., February 1, 2006; 34(2): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Miles, S. T. Stern, P. C. Smith, F. K. Kessler, S. Ali, and J. K. Ritter AN INVESTIGATION OF HUMAN AND RAT LIVER MICROSOMAL MYCOPHENOLIC ACID GLUCURONIDATION: EVIDENCE FOR A PRINCIPAL ROLE OF UGT1A ENZYMES AND SPECIES DIFFERENCES IN UGT1A SPECIFICITY Drug Metab. Dispos., October 1, 2005; 33(10): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kamar, L. Oufroukhi, P. Faure, D. Ribes, O. Cointault, L. Lavayssiere, M. B. Nogier, L. Esposito, D. Durand, and L. Rostaing Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2231 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tian, J. Ou, S. C. Strom, and R. Venkataramanan PHARMACOKINETICS OF TACROLIMUS AND MYCOPHENOLIC ACID ARE ALTERED, BUT RECOVER AT DIFFERENT TIMES DURING HEPATIC REGENERATION IN RATS Drug Metab. Dispos., March 1, 2005; 33(3): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
